Indeed, using MDM2-p53 interaction antagonists has recently become an effective treatment for various preclinical cancer models such as soft tissue sarcoma, acute leukemia, colon cancer, prostate cancer, adenoid cystic cancer [19], neuroblastoma [15, 20, 21], and lung cancer [17, 22]. This evidence concerns the gene TP53 and cancer.